Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.

Abstract: Crystals of [VOBDC](H2BDC)0.71 were synthesized hydrothemally. The guest acid molecules were removed by heating in air to give high quality single crystals of VOBDC. VOBDC was observed to show crystal-to-crystal transformations on absorption of the guest molecules aniline, thiophene and acetone from the liquid phase. Accurate structural data of the guest molecules and framework deformations were obtained from single crystal X-ray data. VOBDC was also shown to absorb selectively thiophene and dimethyl sulphide from methane.

Abstract: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl LeX, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.

Abstract: The present invention generally relies on a process for the preparation of chelated compounds, comprising the selective interaction between a solid matrix and a chelating agent. In more details, the present invention enables the preparation of chelated compounds useful as diagnostic agents, in high yields and in a reliable way.

Abstract: The invention relates to chelate compounds which can be used in MRI, the chelates being intended to be conveyed by lipophilic transporters, such as lipid nanoparticles or liposomes. The invention also relates to compounds comprising, in association, these chelates and these transporters, if appropriate connected via chemical bonding groups, and to their use in diagnostic imaging, it being possible for this association additionally to comprise biological targeting markers, denoted biovectors.

Abstract: Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same. The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.

Abstract: A method for recovering rare earth metals from zeolite-containing waste FCC catalysts comprises an acid leaching step to remove the rare earth metals from the catalyst to form a leachate containing dissolved rare earth metals and separating the rare earth metals from the leachate such as by precipitation.

Abstract: Disclosed is a radioactive bone diagnostic agent which gives a high ratio of radioactivity accumulation in bone to that in blood from an early stage after administration of the agent and allows capturing an image in a short time after administration. Also disclosed is a bisphosphonic acid derivative represented by the following chemical formula (II) or a salt thereof, wherein X represents —(CH2)mCO—, Y represents —(CH2)n—, R represents H, OH, or a halogen atom, m and n are independent of each other and m represents an integer of 1 to 3, and n represents an integer of 0 to 4.

Abstract: The present invention relates to DTPA derivatives capable of forming complexes by combining with metals and the like, metal complexes formed by combining with the DTPA derivatives, MR and CT contrast agents including gold (Au) nano-particles of which surfaces are coated with the metal complexes, and a method for manufacturing the same. The MR and CT contrast agents according to the present invention have a high magnetic relaxation rate, thereby providing an excellent contrast enforcement effect and a long image acquisition time. Furthermore, the MR and CT contrast agents are not toxic to the human body, and are image contrast agents of dual molecules capable of being applied to both MR and CT.

Abstract: The present invention provides compositions and methods based on vital fluorochrome conjugates that are useful for imaging dying and dead cells.

Abstract: The present invention provides a fluorescent rare earth complex having high solubility to a medium, showing fluorescence of high intensity and possessing excellent durability, and also provides a light-emitting element using that complex. The rare earth complex comprises a rare earth ion and a phosphine oxide ligand, and the phosphine oxide ligand contains a phosphorus atom connecting to at least one phenyl group. In the phenyl group, at least one of the meta-positions is substituted. It is also necessary that the para-position of the phenyl group be not substituted.

Abstract: This disclosure relates to contrast agents and compositions comprising the same that are capable of blocking the hydrogen/potassium adenosine triphosphatase enzyme system, and more particularly to the use of such compositions for imaging stomach and colon volume and motility.

Abstract: The invention refers to new chemical compounds belonging to the known class of REE mixed ligand complexes, namely, to the compound of di-(nitrate)acetylacetonatobis (1,10-fenantrolin)lanthanide (III) of the general formula [Ln(NO3)2Acac(Phen)2]*H20, where Ln is TbxEr1-x, Acac is acetylacetonate-ion, Phen is 1,10-fenantrolin in the form suitable for application as a luminescent additive to ink for the hidden marking the valuables to provide protection against forgery. Such additive has three protective features suitable for automatic control independently of each other. The first protective feature is the ability to luminescence in green light under the impact of UV-radiation. The second protective feature is the ability to luminescence in green light under the impact of X-rays. The third protective feature is the Thermo-luminescence, which means the ability to accumulate for indefinite time span the energy of UV- and X-rays with subsequent green light emission at heating.

Abstract: Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films.

Abstract: The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Abstract: A fluorescent gadolinium complex compound comprising a residue of gadolinium.1,4,7,10-tetraazacyclododecane-N,N?,N?,N??-tetraacetic acid or a residue of gadolinium.diethylenetriaminepentaacetic acid bound covalently with a group represented by the following general formula (I) (R1 represents hydrogen atom or a substituent R2, R4, R5 and R7 represent hydrogen atom, a halogen atom or a C1-6 alkyl group, and R3 and R6 represent hydrogen atom, a halogen atom or a C1-6 alkyl group), which is easily taken up into cells and useful as a probe observable by the fluorescence method and MRI.

Abstract: The present invention relates to novel amino acid derivatives containing heterocyclic chelating residues thereof; radioactive or nonradioactive metal complexes thereof; methods for preparation thereof; and apyrogenic and sterile preparative kits of the composition for targeting cancer cells. The compounds of the present invention can easily be taken up to cancer cells as they contain amino acid residues thereof; radioactive or nonradioactive metals can be labeled easily as they contain heterocyclic chelating residues thereof; cancer lesion can be imaged easily by targeting using the present invention.

Abstract: The present invention provides compositions comprising an MRI contrast agent and methods of their use.

Abstract: A compound of formula (I) is provided: wherein: R1 is an optionally substituted 2-(1-azathiaxanthone); each —R2 is independently of the formula —CH2—C(?O)—R4, wherein R4 is an amino acid or a salt thereof, attached to the remainder of R2 through the nitrogen atom of the amino group; and R3 is hydrogen or a C1-6 alkyl group; or wherein: R1 is an optionally substituted 2-(1-azaxanthone); each R2 is independently an optionally substituted glutaric or succinic acid, or a salt or ester thereof; and R3 is hydrogen or a C1-6 alkyl group.

Abstract: A method for preparing an oxalate of one or more actinides for processing and recycling nuclear fuel, comprising: the precipitation of said actinide or the coprecipitation of said actinides in the form of oxalate particles by bringing into contact an aqueous solution containing the actinide(s) with an aqueous solution of oxalic acid or of an oxalic acid salt; and the collection of the resulting oxalate particles; characterized in that the precipitation or coprecipitation is carried out in fluidized bed.

Abstract: The present invention relates to a novel class of paramagnetic ion-based contrast agents of formula (I), wherein a chelating backbone moiety is highly functionalized by the presence of one or more polyhydroxylated chain, that show a pharmacokinetic profile analogous to that of the commonly used T1-general extravascular agents (NSA) but are further characterized by a higher relaxivity.

Abstract: The invention provides modified oligonucleotides of formula (I), comprising at least one metal chelator which provides a powerful tool for study of the pharmacokinetics of siRNA and its correlation with in vivo activity. The chelated metals provide luminescent properties enable detection of the oligonucleotides through the use of time-resolved fluorescent quenching based on energy transfer from the metal ion to a nonfluorescent quencher which can be used as non-isotopic labels of oligonucleotides for diagnostics and evaluation of cellular uptake.

Abstract: A contrast agent for MRI imaging includes: (a) one cyclodextrin, whose truncated-cone-shaped structure defines a central axis, a first and a second openings along the axis, (b) one paramagnetic element, located on the cyclodextrin axis, outside the structure and proximate to the first opening, (c) one or several coordination ligand(s) of the paramagnetic element which coordinate(s) the paramagnetic element, (d) one arm covalently bound to the cyclodextrin, proximate to the second opening, which is able to form an inclusion complex with the cyclodextrin.

Abstract: The invention relates to compounds of formula (I?): in which A, L2, M and B are as defined in the description.

Abstract: A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R1 to R3 represent an alkyl group or alkenyl group; X1 and X2 represent a single bond, —O—, or —N(Z1)- (Z1 represents hydrogen atom, or an alkyl group); X3 to X6 represent —O—, or —N(Z2)- (Z2 represents hydrogen atom, or an alkyl group); n represents an integer of 1 to 10; and L represents a divalent bridging group constituted by atoms selected from the group consisting of carbon atom, hydrogen atom, oxygen atom, nitrogen atom, fluorine atom and sulfur atom.

Abstract: The present invention provides compositions and methods for the synthesis of conjugates of paramagnetic metal ions and nanodiamonds, and uses thereof. In particular, the present invention provides synthesis of paramagnetic metal-nanodiamond conjugates and methods using such compositions as molecular imaging probes.

Abstract: The invention relates to a composite material comprising nanoparticles of at least one metal derivative and at least one type of carboxylic and/or sulfonic acid derivative organic compound chemically bound in a covalent manner with said nanoparticles by means of at least one carboxylic and/or sulfonic function.

Abstract: A device for the investigation of an object uses a microwave transmitter, a microwave receiver, a control device and a contrast medium. The microwave transmitter and the microwave receiver are controlled by the control device. In one embodiment, the following steps maybe implemented: introduction of the contrast medium into the object under investigation; transmission of a microwave signal into the object under investigation by the microwave transmitter; scattering of the microwave signal by the object under investigation and by the contrast medium; and/or reception of the scattered microwave signal by the microwave receiver.

Abstract: A medical magnetic resonance tomography apparatus and a contrast agent for magnetic resonance tomography imaging of cavities in a patient are provided. The contrast agent is formed from a highly viscous magnetic resonance contrast agent. The highly viscous magnetic resonance contrast agent includes a substance. A specific magnetic resonance contrast can be generated by the substance.

Abstract: The invention concerns a system capable of generating a magnetic indication B.sub.o comprising gradients (Gx, Gy, Gz) in certain directions, transmitting ratio frequency wave pulse sequences (RF) perpendicular to B.sub.o in a range of adjustable frequencies, and detecting electromagnetic signals received from a body part (4). The method consists in: injecting a contrast product in said body part, capable of being temporarily fixed in an observed zone (1), and comprising and element capable of causing chemical displacement of a resonance frequency of water hydrogen protons; exciting said body part, using a radio frequency wave pulse sequence: in a range of frequencies adjusted on the basis of the magnetic induction B.sub.o and the chemical displacement for some of said waves: detecting the electromagnetic signals received in said body part, substantially corresponding to the magnetic resonance signals of the protons of the observed zone having undergone the chemical displacement.

Abstract: The invention relates to a process for preparing a polymeric material doped with metal elements, comprising a step of polymerization of at least one monomer comprising at least one ethylenic function, said monomer being complexed with a metal element. Use of the materials obtained by means of this process as catalysts, or luminescent or magnetic materials, or as elements for laser targets.

Abstract: A ligand of Formula (I) is provided: wherein A4 represents a hydrogen atom, a nitro group, an amino group, a thiocyanato group, or —Z—Y, in which Z is a divalent linking group and Y is a group derived from a biocompatible molecule, with the proviso that when X is methylene, A4 cannot be a hydrogen atom or a nitro group. A metal complex having the ligand is also provided and is useful as a blood pool contrast agent or a targeting contrast agent.

Abstract: A functionalized trimetallic nitride endohedral fullerene based material can be represented according to the formula: A3-nXnN@Cm (R)o, wherein: where A and X are one or a combination of the following metal atoms: Sc, Y, La, Ce, Pr, Nd, Gd, Tb, Dy, Ho, Er, Tm, Lu; (n=0-3); N is nitrogen; Cm is a fullerene and m=about 60-about 200; and R is an organic, inorganic, or organometallic species. Related compositions, devices and methods are also described.

Abstract: A rapid, simple and versatile metal organic framework molecule (MOF) synthesis method particularly adapted to make non-linear MOFs includes heating MOF precursors, such as a metal or metal oxide and an organic ligand, in a microwave oven for a period sufficient to achieve crystallization. Microwave-assisted MOF synthesis yields high quality MOF crystals in a reaction time ranging from about 5 seconds to about 2.5 minutes, compared to hours and days required in conventional solvothermal and hydrothermal methods. In addition, microwave assisted methods provide MOF materials with uniform crystal size and well-defined shape. Further, microwave synthesis of MOFs allows the size and shape of MOF crystals to be tailored for use in a wide range applications by manipulating reaction conditions. Secondary growth processes may also be employed to grow larger crystals using seeds obtained from microwave-assisted synthesis methods.

Abstract: The present invention relates to a process for preparing a porous metal organic framework comprising at least two organic compounds coordinated to at least one metal ion, which comprises the steps (a) oxidation of at least one anode comprising the metal corresponding to at least one metal ion in a reaction medium in the presence of at least one first organic compound which is an optionally substituted monocyclic, bicyclic or polycyclic saturated or unsaturated hydrocarbon in which at least two ring carbons have been replaced by heteroatoms selected from the group consisting of N, O and S to form a reaction intermediate comprising the at least one metal ion and the first organic compound; and (b) reaction of the reaction intermediate at a prescribed temperature with at least one second organic compound which coordinates to the at least one metal ion, with the second organic compound being derived from a dicarboxylic, tricarboxylic or tetracarboxylic acid.

Abstract: A compound having superior solubility and suitable for a liposome contrast medium selective for a lesion such as vascular diseases is provided which is represented by the following general formula (I) wherein R1, R2 and R3 independently represent an alkyl group or an alkenyl group having 8 to 25 carbon atoms; X represents —O—, or —N(Z)— (Z represents hydrogen atom, or an alkyl group having 1 to 3 carbon atoms); and L represents a divalent bridging group constituted by atoms selected from the group consisting of carbon atom, hydrogen atom, oxygen atom, nitrogen atom and sulfur atom; Ch represents a functional group represented by the following general formula (II), and in the general formula (II), any one of the hydrogen atom Ha, Hb, Hc, Hd, He, and Hf is substituted with L.

Abstract: This invention includes agents and compositions having MRI, PET, CT, X-ray, SPECT or optical signals, and methods for their use in the determination of a target. In some cases, a MRI, PET, CT, X-ray, SPECT, optical or other signal produced by the agent or composition can be affected by the presence of the target. Examples of targets that can be determined by this invention include, but are not limited to zinc, copper, iron ions and other biological targets. Example of application for imaging in vivo includes the function of pancreas and other organs.

Abstract: Aqueous thermal inkjet ink composition for the printing of security documents comprising at least one luminescent water-soluble lanthanide complex.

Abstract: The invention relates to compounds, to the complexes they form with a lanthanide, and to the use of the complexes for fluorescence marking or NMR imaging. The complex consists of an Ln ion and a ligand R2—C(X—R1)(R3)—NR4R5. R1 is a functional group, X is a single bond or a hydrocarbon-based chain consisting of at least one alkylene or alkenylene group optionally comprising at least one hetero atom or an arylene. R2 is an anionic group A2 or a C1-C4 alkylene or alkenylene group bearing at least one such group A2 and optionally comprising at least one hetero atom. R3 is H or a C1-C5 alkylene or alkenylene group optionally containing at least one hetero atom, and optionally bearing at least one anionic group A3. R4 is a substituent with light-absorbing properties that forms chelate rings with Ln. R5 is a substituent that forms chelate rings with Ln.

Abstract: This invention relates to novel magnetic resonance imaging contrast agents, and methods of making and use thereof.

Abstract: The present invention provides an intermediate film for use in laminated glass, comprising a resin composition containing polyvinyl butyral, a plasticizer and a neodymium compound having compatibility in both the plasticizer and a plasticized resin, where the neodymium compound is a neodymium salt of a polyvalent ester of a dicarboxylic or polycarboxylic acid wherein one carboxyl group is not esterified. The intermediate film is useful in producing a laminated glass.

Abstract: The invention relates to compounds, to the complexes they form with a lanthanide, and to the use of the complexes for fluorescence marking or NMR imaging. The complex consists of an Ln ion and a ligand R2—C(X—R1)(R3)—NR4R5. R1 is a functional group, X is a single bond or a hydrocarbon-based chain consisting of at least one alkylene or alkenylene group optionally comprising at least one hetero atom or an arylene. R2 is an anionic group A2 or a C1-C4 alkylene or alkenylene group bearing at least one such group A2 and optionally comprising at least one hetero atom. R3 is H or a C1-C5 alkylene or alkenylene group optionally containing at least one hetero atom, and optionally bearing at least one anionic group A3. R4 is a substituent with light-absorbing properties that forms chelate rings with Ln. R5 is a substituent that forms chelate rings with Ln.

Abstract: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.

Abstract: The invention relates to an improved method of dynamic nuclear polarisation (DNP) of carboxylic acids and to compounds and compositions for use in the method.

Abstract: Crystals of [VOBDC](H2BDC)0.71 were synthesized hydrothemally. The guest acid molecules were removed by heating in air to give high quality single crystals of VOBDC. VOBDC was observed to show crystal-to-crystal transformations on absorption of the guest molecules aniline, thiophene and acetone from the liquid phase. Accurate structural data of the guest molecules and framework deformations were obtained from single crystal X-ray data. VOBDC was also shown to absorb selectively thiophene and dimethyl sulphide from methane.

Abstract: The invention relates to portable albumin binders, which are useful for improving the pharmacokinetic properties of diagnostic or therapeutic agents, in particular increasing the blood circulations time and/or the tissue penetration capacity of such agents.

Abstract: The invention relates to compounds, to the complexes they form with a lanthanide, and to the use of the complexes for fluorescence marking or NMR imaging. The complex consists of an Ln ion and a ligand R2—C(X—R1)(R3)—NR4R5. R1 is a functional group, X is a single bond or a hydrocarbon-based chain consisting of at least one alkylene or alkenylene group optionally comprising at least one hetero atom or an arylene. R2 is an anionic group A2 or a C1-C4 alkylene or alkenylene group bearing at least one such group A2 and optionally comprising at least one hetero atom. R3 is H or a C1-C5 alkylene or alkenylene group optionally containing at least one hetero atom, and optionally bearing at least one anionic group A3. R4 is a substituent with light-absorbing properties that forms chelate rings with Ln. R5 is a substituent that forms chelate rings with Ln.

Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m—X1p1X2p2X3p3X4p4]z? z B+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.

Abstract: A compound of the formula: wherein R1 is selected from H, methyl, ethyl, carboxyl protecting groups and hydrophilic moieties, R2 and R3 are independently selected from H, methyl, ethyl and carboxyl protecting groups, R4 is selected from H, methyl, ethyl, hydrophilic moieties and carboxyl protecting groups, and R5 is an aryl, heteroaryl, alkyl or a combination of these groups and is substituted with a carbonyl group, an aminooxy group or a functional group suitable for participating in a cycloaddition reaction. The compounds of the invention may be useful as bifunctional chelating agents which allow chemoselective attachment to targeting molecules.

Abstract: The invention relates to a detectable molecule comprising a biospecific binding reactant attached to a luminescent lanthanide chelate comprising a lanthanide ion and a chelating ligand of the formula (I) wherein, R1A R1B are independently of each other selected from the group consisting of hydrogen, methyl, ethyl, —COOH, —COO—, —CH2COOH, —CH2COO—, hydroxyl or OR2; R2 is selected from the group consisting of —CH3, —C(CH3)3, —C(CR4)3, wherein R4 is an alkyl with 1 to 6 carbon atoms, —CH2COOH, —CH2COO?, and appropriate hexose residues; R3 is a linker for coupling to a biospecific binding reactant selected from the group consisting of thiourea (—NH—CS—NH—), aminoacetamide (—NH—CO—CH2—NH—), amide (—NH—CO— and —CO—NH—), aliphatic thioether (—S—), disulfide (—S—S—) and 6-substituted-1,3,5-triazine-2,4-diamine; and the lanthanide ion is selected from the group consisting of europium(III), terbium(III), dysprosium(III) and samarium(III). The invention also relates to corresponding lanthanide chelates.